Konstantinos Ntelis1, Elena E Solomou2, Lazaros Sakkas3, Stamatis-Nick Liossis1, Dimitrios Daoussis4. 1. Division of Rheumatology, Department of Internal Medicine, University of Patras Medical School, Patras University Hospital, 26504 Rion, Patras, Greece. 2. Department of Internal Medicine, University of Patras Medical School, Patras University Hospital, Patras, Greece. 3. Department of Rheumatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece. 4. Division of Rheumatology, Department of Internal Medicine, University of Patras Medical School, Patras University Hospital, 26504 Rion, Patras, Greece. Electronic address: jimdaoussis@hotmail.com.
Abstract
INTRODUCTION: Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, autoimmunity, and widespread dermal and visceral fibrosis. This article summarizes the current knowledge about the potential contribution of platelets in the disease process and the rationale of targeting platelets as an adjunct treatment for SSc. METHODS: We performed an electronic search (Medline) using the keywords platelets, systemic sclerosis, autoimmunity, fibrosis, Raynaud, and pulmonary arterial hypertension. RESULTS: The link that connects vasculopathy, autoimmunity, and fibrosis in SSc remains obscure. Experimental data suggest that platelets are not solely cell fragments regulating hemostasis but they have a pleiotropic role in several biologic processes including immune regulation, vasculopathy, fibrosis, and all key features of SSc. Platelets interplay with the impaired endothelium, can interact with immune cells, and they are storages of bioactive molecules involved in tissue injury and remodeling. The potential role of platelets in the pathogenesis of SSc is further supported by experimental data in animal models of SSc. Platelet-derived serotonin represents a novel target in SSc and serotonin blockade is currently being tested in clinical trials. CONCLUSION: Platelets may be actively involved in the pathogenesis of SSc by activating immune responses and facilitating the fibrotic process. However, definite conclusions cannot be drawn until more data from both basic and clinical research are available.
INTRODUCTION:Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, autoimmunity, and widespread dermal and visceral fibrosis. This article summarizes the current knowledge about the potential contribution of platelets in the disease process and the rationale of targeting platelets as an adjunct treatment for SSc. METHODS: We performed an electronic search (Medline) using the keywords platelets, systemic sclerosis, autoimmunity, fibrosis, Raynaud, and pulmonary arterial hypertension. RESULTS: The link that connects vasculopathy, autoimmunity, and fibrosis in SSc remains obscure. Experimental data suggest that platelets are not solely cell fragments regulating hemostasis but they have a pleiotropic role in several biologic processes including immune regulation, vasculopathy, fibrosis, and all key features of SSc. Platelets interplay with the impaired endothelium, can interact with immune cells, and they are storages of bioactive molecules involved in tissue injury and remodeling. The potential role of platelets in the pathogenesis of SSc is further supported by experimental data in animal models of SSc. Platelet-derived serotonin represents a novel target in SSc and serotonin blockade is currently being tested in clinical trials. CONCLUSION: Platelets may be actively involved in the pathogenesis of SSc by activating immune responses and facilitating the fibrotic process. However, definite conclusions cannot be drawn until more data from both basic and clinical research are available.
Authors: Jelena Blagojevic; G Abignano; J Avouac; L Cometi; M Frerix; S Bellando-Randone; S Guiducci; C Bruni; D Huscher; V K Jaeger; V Lóránd; B Maurer; S Nihtyanova; G Riemekasten; E Siegert; I H Tarner; S Vettori; U A Walker; L Czirják; C P Denton; O Distler; Y Allanore; U Müller-Ladner; A Moggi-Pignone; M Matucci-Cerinic; F Del Galdo Journal: Clin Rheumatol Date: 2019-05-20 Impact factor: 2.980
Authors: Petrus Linge; Paul R Fortin; Christian Lood; Anders A Bengtsson; Eric Boilard Journal: Nat Rev Rheumatol Date: 2018-03-21 Impact factor: 20.543
Authors: Kirk R Schultz; Amina Kariminia; Bernard Ng; Sayeh Abdossamadi; Madeline Lauener; Eneida R Nemecek; Justin T Wahlstrom; Carrie L Kitko; Victor A Lewis; Tal Schechter; David A Jacobsohn; Andrew C Harris; Michael A Pulsipher; Henrique Bittencourt; Sung Won Choi; Emi H Caywood; Kimberly A Kasow; Monica Bhatia; Benjamin R Oshrine; Allyson Flower; Sonali Chaudhury; Donald Coulter; Joseph H Chewning; Michael Joyce; Sureyya Savasan; Anna B Pawlowska; Gail C Megason; David Mitchell; Alexandra C Cheerva; Anita Lawitschka; Shima Azadpour; Elena Ostroumov; Peter Subrt; Anat Halevy; Sara Mostafavi; Geoffrey D E Cuvelier Journal: Blood Date: 2020-04-09 Impact factor: 25.476